logo
Plus   Neg
Share
Email

AstraZeneca FY19 Core Operating Profit Rises; Sales Up 12% - Quick Facts

AstraZeneca plc (AZN.L,AZN) reported profit before tax of $1.55 billion for the year ended 31 December 2019 compared to $1.99 billion, previous year. Earnings per $0.25 ordinary share was $1.03, a decline of 40% (44% at CER). Core operating profit was $6.44 billion, an increase of 13%. Core earnings per share increased by 1% (stable at CER) to $3.50.

Full-year 2019 total revenue increased to $24.38 billion from $22.09 billion, prior year. Product sales increased 12% (15% at CER) to $23.56 billion, driven by the performances of new medicines and Emerging Markets. Sales of new medicines increased by 59% (62% at CER) to $9.91 billion. New medicines represented 42% of total product sales.

For fiscal 2020 at CER, depending on the impact of the coronavirus epidemic, AstraZeneca projects: core earnings per share to increase by a mid- to high-teens percentage; and revenue to increase by a high single-digit to a low double-digit percentage.

A second interim dividend of $1.90 per share has been declared, taking the unchanged full-year dividend per share to $2.80.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT